Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.

Agathocleous, Agathoclis

Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. [electronic resource] - British journal of haematology Nov 2010 - 346-53 p. digital

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1365-2141

10.1111/j.1365-2141.2010.08340.x doi


Adult
Aged
Antibodies, Monoclonal, Murine-Derived--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Boronic Acids--administration & dosage
Bortezomib
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Hematologic Diseases--chemically induced
Humans
Lymphoma, Follicular--drug therapy
Lymphoma, Mantle-Cell--drug therapy
Lymphoproliferative Disorders--drug therapy
Male
Middle Aged
Pyrazines--administration & dosage
Rituximab
Survival Analysis
Treatment Outcome
Waldenstrom Macroglobulinemia--drug therapy